Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.
Home PD, Aroda VR, Blonde L, Guyot P, Shaunik A, Fazeli MS, Goswami H, Kalra S, Pourrahmat MM. Home PD, et al. Diabetes Obes Metab. 2020 Nov;22(11):2170-2178. doi: 10.1111/dom.14136. Epub 2020 Jul 26. Diabetes Obes Metab. 2020. PMID: 32627297
Insulin therapy development beyond 100 years.
Home PD, Mehta R. Home PD, et al. Lancet Diabetes Endocrinol. 2021 Oct;9(10):695-707. doi: 10.1016/S2213-8587(21)00182-0. Epub 2021 Sep 1. Lancet Diabetes Endocrinol. 2021. PMID: 34480874 Review.
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
Home P, Blonde L, Kalra S, Ji L, Guyot P, Brulle-Wohlhueter C, Murray E, Shah R, Sayre T, Shaunik A. Home P, et al. Diabetes Obes Metab. 2020 Nov;22(11):2179-2188. doi: 10.1111/dom.14148. Epub 2020 Sep 3. Diabetes Obes Metab. 2020. PMID: 32700442
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
Bolli GB, Landgraf W, Bosnyak Z, Melas-Melt L, Home PD. Bolli GB, et al. Among authors: home pd. Diabetes Obes Metab. 2020 Sep;22(9):1664-1669. doi: 10.1111/dom.14065. Epub 2020 May 29. Diabetes Obes Metab. 2020. PMID: 32314521 Free PMC article.
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Hollander PA, Carofano WL, Lam RLH, Golm GT, Eldor R, Crutchlow MF, Marcos MC, Rendell MS, Home PD, Gallwitz B, Rosenstock J. Hollander PA, et al. Among authors: home pd. Diabetes Obes Metab. 2018 Sep;20(9):2229-2237. doi: 10.1111/dom.13363. Epub 2018 Jun 10. Diabetes Obes Metab. 2018. PMID: 29761615 Clinical Trial.
Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC. Home PD, et al. Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12. Diabetes Obes Metab. 2015. PMID: 24957785 Free PMC article. Clinical Trial.
335 results